Trial results for guselkumab (also known as Tremfya) in participants with moderately to severely active Crohn's disease were posted on ClinicalTrials.gov on 2025-05-20. The Phase 3 study primarily evaluated safety, reporting that 33 out of 38 participants experienced treatment-emergent adverse events, with 3 serious events.
Background
The study investigated guselkumab in individuals diagnosed with moderately to severely active Crohn's Disease. The purpose of this study was to evaluate the safety of guselkumab in this patient population.
Trial design
The study (NCT04397263) was a Phase 3 trial that enrolled 38 participants with Crohn's Disease. The intervention involved administering guselkumab. The primary focus of the study, as stated in its brief summary, was to evaluate the safety of guselkumab.
Key results
The trial reported safety outcomes for participants receiving guselkumab 200 Milligrams (mg):
- The number of participants with Treatment-emergent Adverse Events (TEAEs) was 33.
- The number of participants with Treatment-emergent Serious Adverse Events (TESAEs) was 3.
- The number of participants with Treatment-emergent Adverse Events of Special Interest (TEAESI) was 0.
Regarding Treatment-emergent Abnormalities in Hematology Laboratory Parameters, the results showed:
- 18 participants experienced abnormalities in one specific hematology parameter.
- 2 participants experienced abnormalities in another specific hematology parameter.
- 3 participants experienced abnormalities in a third specific hematology parameter.
- For several other hematology laboratory parameters, 0 participants experienced abnormalities.
What this means
The posted results provide important safety data for guselkumab in the context of moderately to severely active Crohn's Disease. The findings on treatment-emergent adverse events, including serious events and events of special interest, contribute to the understanding of the drug's safety profile in this patient population. This information is crucial for clinicians assessing the risk-benefit profile of guselkumab for Crohn's disease treatment.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04397263, titled "A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease," were posted on 2025-05-20 on clinicaltrials.gov.